NEVVI Medicare utilization intelligence
or

← back

Provider profile

NAHUM, KENNETH D.O.

Hematology-Oncology · NPI 1922079904 · HOWELL, NJ

1
Groups
48
Codes · 2024
176,702
Disclosed services

NAHUM, KENNETH is a Hematology-Oncology in HOWELL, NJ, a member of 1 medical group, who billed 48 distinct codes to Medicare Part B in 2024.

Groups: REGIONAL CANCER CARE ASSOCIATES LLC (HACKENSACK, NJ)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

176,702
disclosed services
48
codes billed to Medicare Part B
Prior year · CY2023 236,034 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J0185 Injection, aprepitant, 1 mg
J9271 Injection, pembrolizumab, 1 mg
Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J0897 Injection, denosumab, 1 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J2919 Injection, methylprednisolone sodium succinate, 5 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J0640 Injection, leucovorin calcium, per 50 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96413 Administration of chemotherapy into vein, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
J3490 Unclassified drugs
96375 Injection of additional new drug or substance into vein
96372 Injection of drug or substance under skin or into muscle
J3489 Injection, zoledronic acid, 1 mg
J9045 Injection, carboplatin, 50 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
93793 Anticoagulant management of patient taking warfarin
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99195 Drawing of blood for a medical problem
J9190 Injection, fluorouracil, 500 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96411 Administration of additional new drug or substance into vein using push technique
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96361 Infusion into a vein for hydration, each additional hour
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg
J7030 Infusion, normal saline solution , 1000 cc
38222 Biopsy and aspiration of bone marrow sample for diagnosis
96523 Irrigation of implanted venous access drug delivery device

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.